Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
|
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [21] Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    Leung, Yvette
    Urbanski, Stefan J.
    Schindel, Lynn
    Myers, Robert P.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 20 (10) : 661 - 663
  • [22] Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C
    Adams, Shelly
    Ostermeier, Mark
    OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION, 2010, 81 (11) : 580 - 586
  • [23] Pulmonary hazards of chronic hepatitis C virus infection treatment with Pegylated interferon and ribavirin vs. untreated patients
    Elhelaly, Sanaa
    Elgazzar, Alaa Eldin. M.
    Ragab, Mostafa
    Elkomy, Howida
    Fathy, Talaat
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2013, 62 (02): : 325 - 329
  • [24] Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection
    Sulkowski, MS
    Wasserman, R
    Brooks, L
    Ball, L
    Gish, R
    JOURNAL OF VIRAL HEPATITIS, 2004, 11 (03) : 243 - 250
  • [25] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Mosaburo Kainuma
    Norihiro Furusyo
    Eiji Kajiwara
    Kazuhiro Takahashi
    Hideyuki Nomura
    Yuichi Tanabe
    Takeaki Satoh
    Toshihiro Maruyama
    Makoto Nakamuta
    Kazuhiro Kotoh
    Koichi Azuma
    Junya Shimono
    Shinji Shimoda
    Jun Hayashi
    World Journal of Gastroenterology, 2010, 16 (35) : 4400 - 4409
  • [26] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Kainuma, Mosaburo
    Furusyo, Norihiro
    Kajiwara, Eiji
    Takahashi, Kazuhiro
    Nomura, Hideyuki
    Tanabe, Yuichi
    Satoh, Takeaki
    Maruyama, Toshihiro
    Nakamuta, Makoto
    Kotoh, Kazuhiro
    Azuma, Koichi
    Shimono, Junya
    Shimoda, Shinji
    Hayashi, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (35) : 4400 - 4409
  • [27] Antiviral/Immunomodulatory Combination Therapy: Pegylated Interferon Alpha 2a and Ribavirin in Patients with Chronic Hepatitis C Virus Infection
    Delic, Dragan
    Mitrovic, Nikola
    Popovic, Natasa
    Urosevic, Aleksandar
    Pesic, Ivana
    Simonovic, Jasmina
    Dulovic, Olga
    Svirtlih, Neda
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2012, 140 (9-10) : 612 - 618
  • [28] Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin
    Camargo Grossmann, Soraya de Mattos
    Teixeira, Rosangela
    Ferreira de Aguiar, Maria Cassia
    Vieira do Carmoa, Maria Auxiliadora
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (07) : 702 - 706
  • [29] Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia
    Karakan, T
    Cindoruk, M
    Degertekin, B
    Dogan, I
    Sancak, A
    Dumlu, S
    Gorgul, A
    Unal, S
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2005, 66 (03): : 247 - 253
  • [30] Kinetics of hepatitis C virus RNA load during pegylated interferon plus ribavirin therapy in treatment-naive Chinese patients
    Chu, Chi-Jen
    Wang, Yuan-Jen
    Hwang, Shinn-Jang
    Lu, Rei-Hwa
    Chang, Full-Young
    Chang, Chiao-Yu
    Yang, Ya-Chun
    Lee, Shou-Dong
    HEPATO-GASTROENTEROLOGY, 2007, 54 (75) : 866 - 870